West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, United Kingdom; British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; University of New South Wales, Sydney, New South Wales, Australia. Electronic address: https://twitter.com/TomJFord.
Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.
J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2841-2855. doi: 10.1016/j.jacc.2018.09.006. Epub 2018 Sep 25.
Patients with angina symptoms and/or signs of ischemia but no obstructive coronary artery disease (INOCA) pose a diagnostic and therapeutic challenge.
The purpose of this study was to test whether an interventional diagnostic procedure (IDP) linked to stratified medicine improves health status in patients with INOCA.
The authors conducted a randomized, controlled, blinded clinical trial of stratified medical therapy versus standard care in patients with angina. Patients with angina undergoing invasive coronary angiography (standard care) were recruited. Patients without obstructive CAD were immediately randomized 1:1 to the intervention group (stratified medical therapy) or the control group (standard care, IDP sham procedure). The IDP consisted of guidewire-based assessment of coronary flow reserve, index of microcirculatory resistance, fractional flow reserve, followed by vasoreactivity testing with acetylcholine. The primary endpoint was the mean difference in angina severity at 6 months (assessed by the Seattle Angina Questionnaire summary score).
A total of 391 patients were enrolled between November 25, 2016, and November 12, 2017. Coronary angiography revealed obstructive disease in 206 (53.7%). One hundred fifty-one (39%) patients without angiographically obstructive CAD were randomized (n = 76 intervention group; n = 75 blinded control group). The intervention resulted in a mean improvement of 11.7 U in the Seattle Angina Questionnaire summary score at 6 months (95% confidence interval [CI]: 5.0 to 18.4; p = 0.001). In addition, the intervention led to improvements in the mean quality-of-life score (EQ-5D index 0.10 U; 95% CI: 0.01 to 0.18; p = 0.024) and visual analogue score (14.5 U; 95% CI: 7.8 to 21.3; p < 0.001). There were no differences in major adverse cardiac events at the 6-month follow-up (2.6% controls vs. 2.6% intervention; p = 1.00).
Coronary angiography often fails to identify patients with vasospastic and/or microvascular angina. Stratified medical therapy, including an IDP with linked medical therapy, is routinely feasible and improves angina in patients with no obstructive CAD. (CORonary MICrovascular Angina [CorMicA]; NCT03193294).
有胸痛症状和/或缺血迹象但无阻塞性冠状动脉疾病(INOCA)的患者诊断和治疗具有挑战性。
本研究旨在检验介入性诊断程序(IDP)与分层医学相结合是否能改善 INOCA 患者的健康状况。
作者对接受有创冠状动脉造影(标准治疗)的心绞痛患者进行了随机、对照、盲法临床试验,比较了分层药物治疗与标准治疗。招募了无阻塞性 CAD 的心绞痛患者,这些患者立即按 1:1 随机分为干预组(分层药物治疗)或对照组(标准治疗,IDP 假手术)。IDP 包括基于导丝的冠状动脉血流储备、微血管阻力指数、血流储备分数评估,随后进行乙酰胆碱血管反应性测试。主要终点是 6 个月时心绞痛严重程度的平均差异(西雅图心绞痛问卷综合评分评估)。
2016 年 11 月 25 日至 2017 年 11 月 12 日期间共纳入 391 例患者。冠状动脉造影显示 206 例(53.7%)有阻塞性疾病。151 例(39%)无血管造影阻塞性 CAD 的患者被随机分组(n=76 例干预组;n=75 例盲法对照组)。干预组在 6 个月时西雅图心绞痛问卷综合评分平均改善 11.7U(95%置信区间:5.0 至 18.4;p=0.001)。此外,干预组还改善了平均生活质量评分(EQ-5D 指数 0.10U;95%置信区间:0.01 至 0.18;p=0.024)和视觉模拟评分(14.5U;95%置信区间:7.8 至 21.3;p<0.001)。6 个月随访时主要不良心脏事件无差异(对照组 2.6%,干预组 2.6%;p=1.00)。
冠状动脉造影常不能识别出有血管痉挛性和/或微血管性心绞痛的患者。包括与医学治疗相关的 IDP 在内的分层药物治疗通常是可行的,并能改善无阻塞性 CAD 患者的心绞痛。(冠状动脉微血管性心绞痛[CorMicA];NCT03193294)。